Zar Technology Services

At OPXBIO, we’re in the Good Chemistry business. We develop and produce bio-based chemicals and fuels that deliver more sustainable value to our customers. Good Chemistry is everything we do. It is how we use our leading EDGE™ biotechnology to bring new products to market faster. It’s our strategic partnerships. It’s our high-performing team. And it’s our inspiration to transform the business of chemistry to a more sustainable future.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

news image

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More

DIAGNOSTICS

PROVECTUS ALGAE EXPANDS INTO NEW LARGE-SCALE MICROALGAE BIOMANUFACTURING FACILITY

Provectus Algae | August 28, 2021

news image

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...

Read More

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

news image

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More

MEDICAL

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

news image

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More
news image

CELL AND GENE THERAPY

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More
news image

DIAGNOSTICS

PROVECTUS ALGAE EXPANDS INTO NEW LARGE-SCALE MICROALGAE BIOMANUFACTURING FACILITY

Provectus Algae | August 28, 2021

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...

Read More
news image

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More
news image

MEDICAL

SOTIRA ANNOUNCES THE SUCCESSFUL COMPLETION OF SECOND PHASE OF PRE-CLINICAL TESTING FOR COVID-19 THERAPEUTIC AND VACCINE-ALTERNATIVE

Sotira | November 25, 2020

Sotira, the Phoenix based biotech organization, is pleased to report the successful finish of the second period of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming that this cutting-edge molecular therapy completely prevented of SARS-CoV2 in the lungs and kidney. These mice are viewed as a best quality level preclinical model to study COVID-19 on the grounds that the mice express human ACE2, the receptor utilized by the virus to gain ent...

Read More